Herborium Group Expands Sales in United Kingdom By Expanding Agreement with MannKind Biopharmaceuticals
Published: Jun 17, 2010
SADDLE BROOK, NJ--(Marketwire - June 16, 2010) - Herborium Group, Inc., (PINKSHEETS: HBRM) www.herborium.com, a Botanical Therapeutics™ company, today announced that it will be expanding the scope of its distribution arrangements with the renowned direct marketer of male grooming products in the UK, Mankind LLC. Initially, Mankind has distributed Herborium proprietary, novel, herbal acne treatment AcnEase® in the UK and some other European markets to an upscale male segment through e-commerce as well as catalogue channels.
"As Mankind is presently expanding its target market to include female consumers and is planning to move into the retail market in the UK, AcnEase will also gain access to those lucrative markets. With the UK market for natural based products estimated to be over $25 billion, and close to $1 billion spent on natural cosmceuticals including medicated skin care products, and with an assistance of such an experienced partner as Mankind, Herborium capturing just a fraction of this market should result in a substantial growth of revenues," commented Dr. Agnes P. Olszewski, Herborium's CEO and President.
The Dermatology Market Outlook for 2011 forecasts that, collectively, the acne market is estimated to be $2.7 billion in 2011. The major dermatological indications included in this market are acne, the largest segment, and rosacea, the fifth largest segment, both of which are treated successfully by AcnEase. In clinical studies AcnEase® has demonstrated up to 95% efficacy in diminishing acne and improving skin condition.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. Adino Energy Corporation urges investors to review the risks and uncertainties contained within its filings with the Securities and Exchange Commission.
Dr. Agnes P. Olszewski
President & CEO